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EDITORIAL
The main constituent of plaques in the brain of Alzheimer’s disease (AD) individuals namely amyloid beta (Aβ) [1] is a pro-
teolytic product of a larger protein, the amyloid precursor protein (APP) protein. Carriers of the apo E4 allele are at greater risk 
of developing AD with increased deposition of amyloid beta plaques in Western countries. Apo E4 is also a major risk factor for 
cardiovascular disease linked to defective cholesterol metabolism [2,3]. Protein and Aβ homeostasis is now crucial to the lifespan of 
organisms and is an important feature that determines the aging process in obesity, diabetes and neurodegenerative diseases [4]. 
The scientific understanding of the maintenance of peripheral blood plasma Aβ metabolism has now become essential to prevent 
neurodegeneration and is now linked to Type 3 diabetes [5,6]. The concentration of Aβ within the brain is determined by hepatic 
Aβ clearance and interest in the liver has increased markedly since in Western countries the incidence of non-alcoholic fatty liver 
disease (NAFLD) has reached approx. 20% of the developed world and by the year 2050 it may reach to approx. 40% of the global 
population [7]. Induction of Type 3 diabetes disease progression now involves unhealthy diets that corrupts neuron calcium flux 
and the circadian rhythm of the neuron Aβ peptide [8-13] connected to defective peripheral hepatic glucose and Aβ metabolism [4] 
in individuals with NAFLD [4]. The liver is of principal importance and the mechanisms for the clearance of Aβ by the liver involve 
lipoproteins (5%) and albumin (90%) which bind and sequester Aβ for clearance to the liver, preventing the toxic effects of Aβ to 
the heart and brain [4]. Caffeine is hydrophobic and increased consumption can rapidly allow distribution to the liver and adipose 
tissue with rapid transport across the blood brain barrier to neurons [14-17]. In adipose tissue caffeine has been shown to increase 
adinopectin levels with relevance to anti-aging gene activation [18-20] and the adipose tissue-liver crosstalk [21]. Caffeine has become 
important to peripheral Aβ metabolism with suppression of plasma and brain Aβ in AD transgenic mice [22,23] and beneficial effects 
involve prevention of bacterial lipopolysaccharides (LPS) induction of inflammation and Aβ aggregation [24,25]. In the developing 
world increased plasma LPS levels may override caffeine effects with spontaneous Aβ aggregation [26,27]. Caffeine consumption 
over many years’ effects cerebrospinal fluid production (CSF) and increased caffeine binding to albumin may displace Aβ from 
CSF albumin and mediate toxic effects on Aβ oligomer generation relevant to the development of Type 3 diabetes and various 
neurological diseases [28-31].
In global NAFLD epidemic caffeine metabolism is markedly reduced and metabolism of caffeine (4-6 hr) delayed (Figure 1) 
with increased transport of caffeine to the brain with effects on altered neuron calcium signalling relevant to the induction of Type 
3 diabetes and circadian rhythm abnormalities [14-16,32-36]. Caffeine is metabolized mostly by the P450 enzyme system in the body 
and specifically the CYP1A enzymes (CYP1A1, 1A2) [37,38]. The metabolism by hepatic CYP1A enzymes of caffeine follows first-order 
kinetics and is the rate-limiting step of plasma clearance [37,38]. Interest in the anti-aging gene Sirtuin 1 (Sirt 1) in neuron transcrip-
tional responses has accelerated with relevance to Type 3 diabetes [5,6] and the gene Sirt 1 is now connected to the development 
of NAFLD [39,40] with its deacetylation of nuclear pregnane X receptor (PXR) relevant to drug metabolism [39]. Sirt 1/PXR interactions 
are now important to the regulation of the CYP1A enzymes [37,38] with rapid metabolism of caffeine in individuals without NAFLD. 
Caffeine consumption (coffee, coca cola, chocolate, tea, other sources) that was previously recommended to be approx. 200 mg 
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per day and not to exceed to 500-600 mg per day need to be revised (Figure 1) in the current global NAFLD epidemic [40]. Elevated 
caffeine concentrations can override Sirt 1 regulation of cell cycle control and prevention of Sirt 1 regulation of programmed cell 
death [41-43]. Sirt 1 is a histone deacetylase that targets transcription factors such as p53 to adapt gene expression to Aβ metabo-
lism, metabolic activity and insulin resistance [40]. The effect on Sirt 1 modulation of programmed cell death by caffeine involves 
its p53 dependent induction of mitochondrial apoptosis [44-46]. High calorie diets downregulate Sirt 1 with altered drug, choles-
terol, Aβ and caffeine metabolism [38-40]. Caffeine metabolism is now important to statin treatment of brain cholesterol levels with 
drug transport to the brain [6] connected to hepatic caffeine metabolism and caffeine modulation of brain Sirt 1 activity in global 
populations. Sirt 1 activators (leucine, resveratrol, pyruvic acid) compared to the ingestion of Sirt 1 inhibitors (alcohol, palmitic 
acid, suramin, sirtinol, LPS) are now important to the global NAFLD epidemic with relevance to hepatic Sirt 1 regulation of drug, 
caffeine, glucose and Aβ metabolism.
The major side effects of caffeine overconsumption (Figure 1) leads to magnesium and calcium deficiency [47] with relevance 
to insulin resistance and corruption of the peripheral sink Aβ clearance pathways [48]. Magnesium is a Sirt 1 activator with caffeine 
responsible for low brain magnesium levels and induction of Type 3 diabetes [5,6,43]. Levels of plasma magnesium need to be care-
fully evaluated to determine the success of caffeine in the maintenance of glucose homeostasis and Aβ metabolism [49-54]. Sirt 
1 is responsible for neuron synaptic plasticity with Sirt 1 repression relevant to reduced synaptic plasticity and reduced effects 
of caffeine on adenosine A(2A) receptor with relevance to synaptotoxicity and memory dysfunction. Unhealthy diets should be 
avoided to activate Sirt 1 regulation [27] of the circadian rhythm with relevance to glucose, caffeine, Aβ and cholesterol metabo-
lism. Concerns for recent in vivo and in vitro scientific reports with relevance to caffeine effects on delayed circadian rhythm [36] 
interferes with Sirt 1 modulation of circadian rhythm circuitry [35] with relevance to brain glucose and amyloid beta regulation and 
induction of Type 3 diabetes. 
      
Figure 1. In panel A hepatic caffeine metabolism is rapid with a half-life between 4-6 hrs. Caffeine reduce LPS inflammatory effect with reduced 
LPS transport to the brain that allows efficient circadian rhythm circuitry with rapid brain amyloid beta transport to the liver. In panel B the global 
NAFLD epidemic indicates that caffeine consumption should be carefully modified to reduce excessive caffeine transport to the brain that 
induces Type 3 diabetes by interference with magnesium/Sirt 1 activation responsible for neuron proliferation and normal brain glucose and 
amyloid beta metabolism.
CONCLUSION
Major interests in caffeine consumption has increased with the alarming increase in the global NAFLD epidemic relevant 
to increased transport of caffeine to the brain with the induction of Type 3 diabetes. Specific nutritional diets are essential to 
maintain hepatic caffeine metabolism to facilitate rapid Aβ clearance in the periphery and to maintain the effects of drugs such 
as statins to reduce toxic Aβ formation not only in Type 3 diabetes but to various neurological diseases. Anti-aging gene Sirt 1 is 
responsible for brain Aβ and caffeine metabolism and inactivation of Sirt 1 by unhealthy diets is now relevant to Type 3 diabetes 
and premature brain aging. In the current global NAFLD epidemic caffeine consumption should be carefully controlled to maintain 
its role as a Sirt 1 modulator with relevance to caffeine regulation of neuron calcium signaling important to circadian glucose and 
Aβ regulation in Type 3 diabetes.
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